Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of Cinnovex, Rebif and Betaferon on serum BDNF in multiple sclerosis
IRCT2013073114234N1Phase 3Completed
- Sponsor
- Ahvaz Jundishapur University of Medical Sciences
- Start
- Jun 2012
- Modality
- Cytokines & Interferons → Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of cinnarizine + dimenhydrinate and interferon beta-1a in multiple sclerosis (MS) (3 arms), sponsored by Ahvaz Jundishapur University of Medical Sciences. Primary endpoint: Change in serum brain-derived neurotrophic factor (BDNF) level. Started Jun 2012; status: completed.
02
Drugs
cinnarizine + dimenhydrinateinterferon beta-1a
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on IRCT2013073114234N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2013073114234N1.